Area of research
Hepatology · Infectious Diseases
Research interest
Research interests include Hepatitis C virus research, HIV/AIDS drug development and treatment, COVID-19 Clinical Research Studies, and Vascular Anomalies and Treatments.
Efficacy and safety of obeldesivir in low-risk, non-hospitalised patients with COVID-19 (OAKTREE): a phase 3, randomised, double-blind, placebo-controlled study
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19
Identification of 19 Novel Hepatitis C Virus Subtypes—Further Expanding HCV Classification
No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients
Deferred treatment with sofosbuvir–velpatasvir–voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials
Ledipasvir–sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders
Treatment With Ledipasvir–Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection
Perioperative Ledipasvir–Sofosbuvir for HCV in Liver-Transplant Recipients
Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial